Skip to content
Bored Studies
RecruitingPhase 2

A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)

Eli Lilly and Company · NCT07533006

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–60 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 2
Target enrollment
60
US sites recruiting
9
Study start
April 14, 2026
Record last updated
October 9, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The purpose of this study is to evaluate how well LY4005130 works in participants with severe alopecia areata (hair loss) when compared with placebo, and how well it's tolerated and what side effects may occur. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.

The study drug will be administered intravenously (IV) (into a vein in the arm).

The study will last approximately 48 weeks, including screening.

Being studied: LY4005130; Placebo

Conditions: Alopecia Areata

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Have severe Alopecia Areata (AA) that meets all of the following criteria:
  • Hair loss encompassing ≥50% and ≤90% of the scalp, as measured by Severity of Alopecia Tool (SALT) score
  • The duration of the current episode of severe AA is at least 6 months and does not exceed 4 years
  • No significant spontaneous hair regrowth in the investigator's opinion for at least 6 months
  • Agree not to use any AA treatments during the study

Exclusion Criteria

  • Primarily "diffuse" type of AA (characterized by diffuse hair shedding)
  • Are currently experiencing other forms of alopecia
  • Participants who, in the opinion of the investigator, are currently experiencing or have a history of unstable concomitant disease that requires frequent hospitalizations, and/or frequent use of systemic immunosuppressants that may interfere with participation in the study
  • Have had any major surgery within 8 weeks prior to screening or will require major surgery during the study
  • Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness

Recruiting US locations

  • Center For Dermatology Clinical Research, Inc.

    Fremont, CA 94538

    Site contact: 5107970140

  • Northridge Clinical Trials

    Northridge, CA 91325

    Site contact: 818-350-7482

  • Cura Clinical Research - Santa Clarita - Kelly Johnson Parkway

    Santa Clarita, CA 91355

    Site contact: 833-525-2872

  • Health Clinical Research, LLC

    Cutler Bay, FL 33189

    Site contact: 7862801977

  • Brigham and Women's Hospital

    Boston, MA 02115

    Site contact: 6177324918

  • Revival Research Institute, LLC

    Troy, MI 48084

    Site contact: 2485900298

  • Stracskin

    Portsmouth, NH 03801

    Site contact: 6178339995

  • Texas Dermatology and Laser Specialists - San Antonio - South New Braunfels Avenue

    San Antonio, TX 78235

    Site contact: 2108522779

  • Jordan Valley Dermatology & Research Center

    South Jordan, UT 84095

    Site contact: Douglass Forsha

Study contacts (from the official record)

  • Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · 1-317-615-4559 · LillyTrials@Lilly.com
  • Physicians interested in becoming principal investigators please contact · clinical_inquiry_hub@lilly.com
All dermatology studies in California →
A Study of LY4005130 in Adult Participants With Severe Alopecia… (NCT07533006) | Bored Studies